Drug Type Antibody fusion proteins |
Synonyms- |
Mechanism EBOV glycoprotein inhibitors(EBOV glycoprotein inhibitors), HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists), IL-10 modulators(Interleukin-10 modulators) + [1] |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | US | 29 Feb 2024 |